T淋巴細胞如何被激活?
細胞治療領域中T細胞的激活
為支持細胞治療藥物的開發，ACROBiosystems?自主開發了高質量的CD3/CD28抗體偶聯磁珠產品（貨號：MBS-C001），經細胞水平驗證，可高效刺激擴增T細胞，更好的助力細胞治療藥物的開發進程。
?
★?5.5 μm大小，可更好的模擬APC，刺激T細胞
★?磁性強，輕松分離，磁珠不易殘留
★?超低內毒素（< 2EU/mg），對T細胞無傷害
★?經細胞水平驗證，可高效激活擴增T細胞
??Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No.?MBS-C001) 可高效激活T細胞
???經Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No.?MBS-C001)?刺激后，可對T細胞進行有效擴增
競品對比數據
The purified human T cells were activated using ACRO Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No.?MBS-C001) and competitor’s beads respectively at a ratio of 1:1 beads-to-cells for 24 hours with RPMI1640 supplemented with 10% of FBS. Cells were fluorescently stained using PE labeled anti-human CD25 antibody and labeled FITC anti-human CD69 antibody and analyzed by flow cytometry.
與競品相比，ACRO Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No.?MBS-C001)，可對T細胞進行有效擴增，且有較高水平的擴增能力
The purified human T cells were stimulated using Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No.?MBS-C001) and competitor’s beads respectively. Cells were expanded in T cell culture medium supplemented with 4ng/mL of rhIL-2 Protein (Acrobiosystems, Cat. No. IL2-H4113). Activated Cells were expanded for up to 13 days (A) with high cell viability (B).
★更多T細胞激活試劑Anti-CD3 antibody（clone: OKT3Anti-CD28 antibod
GMP級別細胞因子
?
ACROBiosystems
inquiry@acrobiosystems.com
15117918562
（備注：姓名+公司）
?
參考文獻
[1] Kay, J.E., 1991. Mechanisms of T lymphocyteactivation. Immunology Letters 29, 51 – 54
[2] 醫學免疫學-第7版
[3] Trickett A, Kwan YL. T cellstimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods. 2003Apr 1;275(1-2):251-5.
[4] Kalos M, Levine BL, Porter DL, KatzS, Grupp SA, Bagg A, June CH: T cells with chimeric antigen receptors havepotent antitumor effects and can establish memory in patients with advancedleukemia. Sci Transl Med 2011, 3:95ra73.
[5] Hollyman D, Stefanski J, PrzybylowskiM, Bartido S, Borquez- Ojeada O, Taylor C, Yeh R, Capacio V, Olszewska M, HoseyJ et al.: Manufacturing validation of biologically functional T cells targetedto CD19 antigen for autologous adoptive cell therapy. J Immunother 2009, 32:169-180.
[6]Casati A, Varghaei-Nahvi A, FeldmanSA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A: Clinical-scaleselection and viral transduction of human na?¨ve and central memory CD8+ T cells for adoptive cell therapy ofcancer patients. Cancer Immunol Immunother 2013, 62:1563-1573.
[7] Barrett DM, Singh N, Liu X, JiangS, June CH, Grupp SA, Zhao Y: Relation of clinical culture method to T-cellmemory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy2014, 16:619-630.
?